DM
AGRX

Deerfield Management’s Agile Therapeutics AGRX Stock Holding History

Deerfield Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-796
Closed -$1.89M – 101
2019
Q3 		$1.89M Buy
+796
New +$1.96M 0.08% 86
2017
Q4 		– Sell
-611
Closed -$5.45M – 107
2017
Q3 		$5.45M Buy
611
+133
+28% +$1.02M 0.25% 78
2017
Q2 		$3.58M Sell
478
-8
-2% -$55.4K 0.19% 75
2017
Q1 		$3.11M Buy
486
+287
+144% +$1.44M 0.12% 93
2016
Q4 		$2.27M Buy
199
+74
+59% +$1.04M 0.09% 91
2016
Q3 		$1.75M Hold
125
– – 0.08% 80
2016
Q2 		$1.9M Hold
125
– – 0.07% 87
2016
Q1 		$1.55M Buy
+125
New +$1.61M 0.07% 90
2015
Q2 		– Sell
-53
Closed -$973K – 139
2015
Q1 		$973K Hold
53
– – 0.03% 111
2014
Q4 		$645K Hold
53
– – 0.02% 108
2014
Q3 		$767K Buy
53
+1
+2% +$15.4K 0.03% 123
2014
Q2 		$904K Buy
+52
New +$752K 0.04% 112

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return

Deerfield Management's AGRX Position: Q4 2019 in Review

Deerfield Management sold out of Agile Therapeutics (AGRX) in Q4 2019, closing a stake of 796 shares — an estimated $1.89M sold.

Deerfield Management first reported a position in AGRX in Q2 2014 and held it in 12 quarters. The position peaked at $5.45M in Q3 2017. 46 funds tracked by Wall St. Rank hold AGRX as of Q4 2019.

  • Deerfield Management reported no remaining Agile Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Deerfield Management sold 796 Agile Therapeutics shares in Q4 2019, an estimated $1.89M.
  • Deerfield Management first reported a position in Agile Therapeutics in Q2 2014 and held it in 12 quarters.
  • Deerfield Management's Agile Therapeutics position peaked at $5.45M in Q3 2017.
  • 46 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2019.

Based on Deerfield Management's 13F filing for Q4 2019, filed 14 Feb 2020.